Preferred Label : Everolimus;

MeSH definition : A derivative of sirolimus and an inhibitor of TOR SERINE-THREONINE KINASES. It is used to prevent GRAFT REJECTION in heart and kidney transplant patients by blocking cell proliferation signals. It is also an ANTINEOPLASTIC AGENT.;

MeSH synonym : SDZ RAD; RAD, SDZ; SDZ-RAD; 40-O-(2-hydroxyethyl)-rapamycin;

MeSH hyponym : RAD 001; certican; Afinitor; 001, RAD; RAD001;

Wikipedia link : https://en.wikipedia.org/wiki/Everolimus;

Is substance : O;

UNII : 9HW64Q8G6G;

Details


Main resources

You can consult :

A derivative of sirolimus and an inhibitor of TOR SERINE-THREONINE KINASES. It is used to prevent GRAFT REJECTION in heart and kidney transplant patients by blocking cell proliferation signals. It is also an ANTINEOPLASTIC AGENT.

https://www.has-sante.fr/jcms/p_3449186/fr/xience-prime
2023
France
health technology assessment
Everolimus
everolimus
pharmacologist
Endoprosthesis
pharmacology
stents

---
https://www.has-sante.fr/jcms/p_3433900/fr/promus-elite
2023
France
health technology assessment
everolimus
pharmacology
stents
Endoprosthesis
Everolimus
pharmacologist

---
https://www.has-sante.fr/jcms/p_3449192/fr/xience-v
2023
France
health technology assessment
Endoprosthesis
pharmacology
everolimus
Everolimus
pharmacologist
stents

---
https://www.has-sante.fr/jcms/p_3327274/fr/promus-element-plus
2022
France
health technology assessment
pharmacology
elements
Everolimus
chemical element, nos
everolimus
stents
pharmacologist

---
https://www.has-sante.fr/jcms/p_3368517/fr/xience-skypoint
2022
France
health technology assessment
Everolimus
pharmacologist
stents
pharmacology
everolimus

---
https://www.has-sante.fr/jcms/p_3364726/fr/promus-premier
2022
France
health technology assessment
pharmacology
stents
pharmacologist
Everolimus
everolimus

---
https://www.has-sante.fr/jcms/p_3346126/fr/synergy
2022
France
health technology assessment
stents
everolimus
Everolimus
pharmacology
pharmacologist

---
https://www.has-sante.fr/jcms/p_3286658/fr/xience-skypoint
2021
France
pharmacologist
stents
pharmacology
everolimus
Everolimus
health technology assessment

---
https://www.has-sante.fr/jcms/p_3279489/fr/xience-xpedition-48
2021
false
false
false
France
health technology assessment
Everolimus
stents
everolimus
pharmacology
pharmacologist

---
https://www.has-sante.fr/jcms/p_3169462/fr/synergy-megatron
2020
France
health technology assessment
pharmacology
stents
Everolimus
pharmacologist
everolimus

---
https://www.has-sante.fr/jcms/p_3098032/fr/afinitor
2020
false
false
false
France
survival analysis
antineoplastic combined chemotherapy protocols
Everolimus
everolimus
administration, oral
antineoplastic agents
protein kinase inhibitors
treatment outcome
insurance, health, reimbursement
breast neoplasms
Advanced breast cancer
exemestane
hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer
postmenopause
evaluation of the transparency committee
androstadienes

---
https://www.has-sante.fr/jcms/p_3199003/fr/synergy-xd
2020
France
health technology assessment
everolimus
pharmacology
stents
Everolimus
pharmacologist

---
https://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Medicament-ciblant-MTOR-everolimus
2019
false
false
false
France
Everolimus
Drug-Related side effects and adverse reactions
Drug-Related side effects and adverse reactions
antineoplastic agents
antineoplastic agents
protein kinase inhibitors
protein kinase inhibitors
TOR Serine-Threonine kinases
everolimus
administration, oral
patient education as topic
risk factors
carcinoma, renal cell
breast neoplasms
neuroendocrine tumors
Digestive System Neuroendocrine Tumor
Lung Neuroendocrine Neoplasm
gastrointestinal neoplasms
lung neoplasms
pancreatic neoplasms
Pancreatic Neuroendocrine Tumor
adult
drug interactions
continuity of patient care
pregnancy
guidelines for drug use
Everolimus

---
https://www.has-sante.fr/jcms/p_3116858/fr/promus-element-plus-monorail-btk
2019
false
false
false
France
health technology assessment
everolimus
chemical element, nos
Everolimus
elements
stents

---
https://www.has-sante.fr/jcms/p_3116855/fr/promus-element-plus-over-the-wire-btk
2019
France
health technology assessment
Everolimus
tea
tea, nos
chemical element, nos
everolimus
stents
elements
tetrahydrocortisone

---
https://www.has-sante.fr/jcms/p_3115332/fr/promus-premier-btk-promus-premier-over-the-wire-btk-et-promus-premier-monorail-btk
2019
France
health technology assessment
Everolimus
tea, nos
stents
tea
tetrahydrocortisone
Drug-Eluting stents
everolimus
stents

---
https://www.has-sante.fr/jcms/p_3080464/fr/votubia
2019
false
false
false
France
astrocytoma, subependymal giant cell
tuberous sclerosis
angiomyolipoma
Kidney Angiomyolipoma
everolimus
kidney neoplasms
treatment outcome
adult
antineoplastic agents
Everolimus
insurance, health, reimbursement
child
evaluation of the transparency committee
astrocytoma

---
https://www.has-sante.fr/portail/jcms/c_2910489/fr/xience-sierra
2019
false
true
false
false
France
coronary disease
coronary disease
health technology assessment
everolimus
Everolimus
stents

---
https://www.has-sante.fr/portail/jcms/c_2910513/fr/xience-xpedition
2019
false
true
false
false
France
coronary disease
coronary disease
health technology assessment
everolimus
Everolimus
stents

---
https://www.has-sante.fr/portail/jcms/c_2911270/fr/xience-alpine
2019
false
true
false
false
France
coronary disease
coronary disease
coronary disease
health technology assessment
stents
Everolimus
everolimus
pharmacologist

---
https://www.has-sante.fr/portail/jcms/c_2882656/fr/synergy
false
false
false
France
health technology assessment
pharmacologist
pharmacology
everolimus
Everolimus
stents

---
https://www.has-sante.fr/portail/jcms/c_2882647/fr/promus-premier
France
health technology assessment
pharmacology
stents
Everolimus
everolimus
pharmacologist

---
https://www.has-sante.fr/portail/jcms/c_2882650/fr/promus-elite
France
health technology assessment
Everolimus
everolimus
stents
pharmacologist
pharmacology

---
https://www.has-sante.fr/portail/jcms/c_2857763/fr/votubia
2018
false
false
France
French
Everolimus
adult
spasms, infantile
epilepsies, partial
administration, oral
everolimus
insurance, health, reimbursement
tuberous sclerosis
child
treatment outcome
evaluation of the transparency committee

---
https://www.has-sante.fr/portail/jcms/c_2780977/fr/afinitor
https://www.has-sante.fr/portail/jcms/c_2780977/fr/afinitor-everolimus-inhibiteur-de-tyrosine-kinase
2017
false
false
France
French
evaluation of the transparency committee
Advanced Malignant Neoplasm
Everolimus
Everolimus
antineoplastic agents
antineoplastic agents
gastrointestinal neoplasms
lung neoplasms
Lung Neuroendocrine Neoplasm
Digestive System Neuroendocrine Tumor
guidelines for drug use
administration, oral
insurance, health, reimbursement
adult
neoplasm metastasis
everolimus
neuroendocrine tumors
disease progression
treatment outcome
survival analysis

---
https://www.has-sante.fr/portail/jcms/c_2801860/fr/absorb
2017
false
false
false
France
French
health technology assessment
pharmacology
pharmacologic
stents
everolimus
pharmacologist
Everolimus
active

---
https://www.has-sante.fr/portail/jcms/c_2801866/fr/absorb-gt1
2017
false
false
false
France
French
health technology assessment
stents
pharmacologist
everolimus
pharmacologic
pharmacology
Everolimus
active

---
http://www.has-sante.fr/portail/jcms/c_2590004/fr/absorb-gt1
2016
false
false
false
false
France
French
Drug-Eluting stents
coronary disease
blood vessel prosthesis implantation
blood vessel prosthesis
Everolimus

---
http://www.has-sante.fr/portail/jcms/c_1350943/gamme-xience-prime-endoprothese-coronaire-a-liberation-de-principe-actif
http://www.has-sante.fr/portail/jcms/c_1350941/xience-prime-18-decembre-2012-4260-avis
http://www.has-sante.fr/portail/jcms/c_1350942/xience-prime-18-decembre-2012-4364-avis
false
France
French
ACTIVE CORONARY STENT
Everolimus
Drug-Eluting stents
coronary artery disease
health technology assessment
treatment outcome

---
http://www.has-sante.fr/portail/jcms/c_2590001/fr/absorb
http://www.has-sante.fr/portail/jcms/c_2590000/fr/absorb
2016
false
false
false
false
France
French
health technology assessment
immunosuppressive agents
Drug-Eluting stents
coronary artery disease
Everolimus

---
http://www.has-sante.fr/portail/jcms/c_2657488/fr/synergy
2016
false
false
false
false
France
French
health technology assessment
Drug-Eluting stents
Everolimus
coronary disease

---
http://www.has-sante.fr/portail/jcms/c_2722048/fr/certican
2016
true
France
French
corticosteroid therapy
Everolimus
everolimus
administration, oral
immunosuppressive agents
insurance, health, reimbursement
drug therapy, combination
adult
graft rejection
kidney transplantation
heart transplantation
evaluation of the transparency committee
liver transplantation
treatment outcome

---
http://www.has-sante.fr/portail/jcms/c_2589175/fr/afinitor
2016
true
France
French
evaluation of the transparency committee
breast neoplasms
carcinoma, renal cell
Pancreatic Neuroendocrine Tumor
Advanced Malignant Neoplasm
Advanced breast cancer
Everolimus
Everolimus
antineoplastic agents
antineoplastic agents
administration, oral
insurance, health, reimbursement
adult
neoplasm metastasis
everolimus
neuroendocrine tumors
pancreatic neoplasms
disease progression
treatment outcome
survival analysis

---
http://www.has-sante.fr/portail/jcms/c_2658507/fr/votubia
2016
false
France
French
Everolimus
antineoplastic agents
protein kinase inhibitors
angiomyolipoma
Kidney Angiomyolipoma
adult
administration, oral
everolimus
insurance, health, reimbursement
orphan drug production
astrocytoma
astrocytoma, subependymal giant cell
tuberous sclerosis
child
brain neoplasms
treatment outcome
TOR Serine-Threonine kinases
evaluation of the transparency committee

---
http://www.has-sante.fr/portail/jcms/c_2011476/fr/promus-element-plus
http://www.has-sante.fr/portail/jcms/c_2011475/fr/promus-element-plus
2015
false
false
false
France
French
Drug-Eluting stents
immunosuppressive agents
health technology assessment
coronary artery disease
Everolimus
treatment outcome

---
http://www.has-sante.fr/portail/jcms/c_2011473/fr/promus-premier
http://www.has-sante.fr/portail/jcms/c_2011472/fr/promus-premier
2015
false
false
false
false
France
French
health technology assessment
coronary artery disease
Drug-Eluting stents
blood vessel prosthesis
blood vessel prosthesis implantation
immunosuppressive agents
Everolimus
treatment outcome

---
http://www.has-sante.fr/portail/jcms/c_2013081/fr/xience-alpine
http://www.has-sante.fr/portail/jcms/c_2013080/fr/xience-alpine
2015
false
false
false
false
France
French
immunosuppressive agents
Drug-Eluting stents
health technology assessment
coronary artery disease
blood vessel prosthesis
blood vessel prosthesis implantation
Everolimus
treatment outcome

---
http://www.has-sante.fr/portail/jcms/c_2021476/fr/synergy
2015
false
false
false
false
France
French
Drug-Eluting stents
coronary artery disease
immunosuppressive agents
health technology assessment
Everolimus
treatment outcome

---
http://www.has-sante.fr/portail/jcms/c_2062737/fr/promus-premier-btk-over-the-wire
http://www.has-sante.fr/portail/jcms/c_2062736/fr/promus-premier-over-the-wire
2015
false
false
false
false
France
French
health technology assessment
Drug-Eluting stents
blood vessel prosthesis
blood vessel prosthesis implantation
arterial occlusive diseases
lower extremity
immunosuppressive agents
Everolimus

---
http://www.has-sante.fr/portail/jcms/c_2062734/fr/promus-premier-btk-monorail
http://www.has-sante.fr/portail/jcms/c_2062733/fr/promus-premier-monorail-btk
2015
false
false
false
false
France
French
health technology assessment
Drug-Eluting stents
blood vessel prosthesis
blood vessel prosthesis implantation
immunosuppressive agents
arterial occlusive diseases
lower extremity
Everolimus

---
http://www.has-sante.fr/portail/jcms/c_2055706/fr/afinitor
2015
false
France
French
evaluation of the transparency committee
breast neoplasms
carcinoma, renal cell
Everolimus
Everolimus
administration, oral
insurance, health, reimbursement
adult
neoplasm metastasis
everolimus
neuroendocrine tumors
pancreatic neoplasms
disease progression
treatment outcome
randomized controlled trials as topic
disease-free survival
survival analysis

---
http://www.has-sante.fr/portail/jcms/c_2027898/fr/afinitor
http://www.has-sante.fr/portail/jcms/c_1528334/fr/afinitor
http://www.has-sante.fr/portail/jcms/c_2027898/fr/afinitor-everolimus-inhibiteur-de-tyrosine-kinase
2015
false
France
French
Advanced breast cancer
Locally advanced breast cancer
guidelines for drug use
TOR Serine-Threonine kinases
protein kinase inhibitors
Everolimus
evaluation of the transparency committee
everolimus
administration, oral
antineoplastic combined chemotherapy protocols
exemestane
antineoplastic agents
treatment outcome
breast neoplasms
insurance, health, reimbursement
postmenopause
neoplasms, hormone-dependent
randomized controlled trials as topic
Progression-Free survival
disease-free survival
survival analysis
androstadienes

---
http://www.has-sante.fr/portail/jcms/c_2007294/fr/votubia
2014
true
France
French
infant
Everolimus
Everolimus
antineoplastic agents
antineoplastic agents
protein kinase inhibitors
protein kinase inhibitors
administration, oral
everolimus
insurance, health, reimbursement
orphan drug production
astrocytoma
astrocytoma, subependymal giant cell
tuberous sclerosis
child
brain neoplasms
treatment outcome
rare diseases
pharmacovigilance
TOR Serine-Threonine kinases
guidelines for drug use
evaluation of the transparency committee

---
http://www.revmed.ch/RMS/2014/RMS-N-431/Resistance-a-l-endocrinotherapie-dans-le-cancer-du-sein-mecanismes-et-implications-cliniques
2014
false
false
false
Switzerland
French
breast neoplasms
journal article
antineoplastic agents, hormonal
drug resistance, neoplasm
Everolimus
Everolimus
TOR Serine-Threonine kinases
protein kinase inhibitors
protein kinase inhibitors

---
http://www.has-sante.fr/portail/jcms/c_2003867/fr/xience-prime
http://www.has-sante.fr/portail/jcms/c_2003866/fr/xience-prime
2014
false
false
false
false
France
French
Drug-Eluting stents
coronary artery disease
blood vessel prosthesis
blood vessel prosthesis implantation
health technology assessment
ACTIVE CORONARY STENT
Everolimus
treatment outcome

---
http://www.has-sante.fr/portail/jcms/c_1733327/fr/promus-premier
http://www.has-sante.fr/portail/jcms/c_1733326/fr/promus-premier
2014
false
France
French
health technology assessment
Drug-Eluting stents
coronary artery disease
ACTIVE CORONARY STENT
Everolimus
treatment outcome

---
http://www.has-sante.fr/portail/jcms/c_1733330/fr/promus-element-plus
http://www.has-sante.fr/portail/jcms/c_1733329/fr/promus-element-plus
2014
false
France
French
Drug-Eluting stents
coronary artery disease
health technology assessment
ACTIVE CORONARY STENT
Everolimus
treatment outcome

---
http://www.has-sante.fr/portail/jcms/c_1716229/fr/xience-prime
http://www.has-sante.fr/portail/jcms/c_1716228/fr/xience-prime
2013
false
France
French
Drug-Eluting stents
health technology assessment
coronary artery disease
immunosuppressive agents
ACTIVE CORONARY STENT
Everolimus
treatment outcome

---
http://www.has-sante.fr/portail/jcms/c_1716226/fr/xience-xpedition
http://www.has-sante.fr/portail/jcms/c_1716225/fr/xience-xpedition
2013
false
France
French
Drug-Eluting stents
coronary artery disease
health technology assessment
immunosuppressive agents
ACTIVE CORONARY STENT
Everolimus
treatment outcome

---
http://www.has-sante.fr/portail/jcms/c_1716211/fr/xience-v
http://www.has-sante.fr/portail/jcms/c_1716210/fr/xience-v
2013
false
France
French
Drug-Eluting stents
immunosuppressive agents
coronary artery disease
health technology assessment
ACTIVE CORONARY STENT
Everolimus
treatment outcome

---
http://www.has-sante.fr/portail/jcms/c_1622347/fr/certican-everolimus-immunosuppresseur
http://www.has-sante.fr/portail/jcms/c_1648053/fr/certican-synthese-ct12787
2013
false
France
French
corticosteroid therapy
Everolimus
Everolimus
treatment outcome
administration, oral
drug therapy, combination
everolimus
liver transplantation
immunosuppressive agents
graft rejection
insurance, health, reimbursement
clinical trials, phase iii as topic
immunosuppressive agents
guidelines for drug use
evaluation of the transparency committee

---
http://www.has-sante.fr/portail/jcms/c_1647377/fr/gamme-xience-xpedition
http://www.has-sante.fr/portail/jcms/c_1647376/fr/gamme-xience-xpedition
2013
false
France
French
ACTIVE CORONARY STENT
Everolimus
Drug-Eluting stents
coronary artery disease
health technology assessment
treatment outcome

---
http://www.has-sante.fr/portail/jcms/c_1625028/fr/xience-prime-btk
http://www.has-sante.fr/portail/jcms/c_1625027/fr/xience-prime-btk
2013
false
France
French
PERIPHERAL STENT, OTHER
Everolimus
Drug-Eluting stents
health technology assessment
arterial occlusive diseases
lower extremity
immunosuppressive agents
treatment outcome

---
http://www.has-sante.fr/portail/jcms/c_1536376/fr/synergy
http://www.has-sante.fr/portail/jcms/c_1536384/fr/synergy
2013
false
France
French
ACTIVE CORONARY STENT
Everolimus
Drug-Eluting stents
coronary disease

---
http://www.has-sante.fr/portail/jcms/c_1598316/fr/promus-premier-systeme-de-stent-coronaire-a-elution-d-everolimus
http://www.has-sante.fr/portail/jcms/c_1598315/fr/promus-premier-14-mai-2013-4440-avis
2013
false
France
French
CORONARY STENT, OTHER
Everolimus
Drug-Eluting stents
coronary artery disease
health technology assessment
treatment outcome

---
http://www.has-sante.fr/portail/jcms/c_1525543/fr/votubia-everolimus-inhibiteur-de-la-mtor
2013
false
France
French
Everolimus
everolimus
angiomyolipoma
TOR Serine-Threonine kinases
guidelines for drug use
evaluation of the transparency committee
administration, oral
tuberous sclerosis
adult
angiomyolipoma
risk factors
insurance, health, reimbursement
antineoplastic agents

---
http://www.has-sante.fr/portail/jcms/c_973824/certican
http://www.has-sante.fr/portail/jcms/c_1622347/fr/certican
http://www.has-sante.fr/portail/jcms/c_1622346/fr/certican-26062013-avis-ct12787
http://www.has-sante.fr/portail/display.jsp?id=c_400116
2013
false
France
French
guidelines for drug use
corticosteroid therapy
Everolimus
everolimus
administration, oral
immunosuppressive agents
insurance, health, reimbursement
drug therapy, combination
adult
graft rejection
kidney transplantation
heart transplantation
evaluation of the transparency committee
liver transplantation
treatment outcome
clinical trials, phase iii as topic

---
https://www.ema.europa.eu/medicines/human/EPAR/Afinitor
2012
false
United Kingdom
English
French
syndication feed
Everolimus
Everolimus
orphan drug production
drug approval
treatment outcome
tablets
administration, oral
rare diseases
carcinoma, renal cell
adult
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
everolimus
intracellular signaling peptides and proteins
protein kinase inhibitors
protein kinase inhibitors
TOR Serine-Threonine kinases
breast neoplasms
pancreatic neoplasms
neuroendocrine tumors
drug evaluation
summary of product characteristics
package leaflet

---
http://www.has-sante.fr/portail/jcms/c_1294033/afinitor-synthese-28032012
http://www.has-sante.fr/portail/jcms/c_1241934/afinitor-28032012-avis-ct11775
http://www.has-sante.fr/portail/jcms/c_1294096/afinitor-everolimus-inhibiteur-de-la-tyrosine-kinase
2012
false
France
French
evaluation of the transparency committee
guidelines for drug use
Everolimus
administration, oral
protein kinase inhibitors
pancreatic neoplasms
neuroendocrine tumors
everolimus
disease-free survival
TOR Serine-Threonine kinases
insurance, health, reimbursement
adult
neoplasm metastasis
treatment outcome
randomized controlled trials as topic

---
http://www.has-sante.fr/portail/jcms/c_1350944/gamme-xience-v-endoprothese-coronaire-a-liberation-de-principe-actif
http://www.has-sante.fr/portail/jcms/c_1350947/xience-v-18-decembre-2012-4244-avis
http://www.has-sante.fr/portail/jcms/c_1350948/xience-v-18-decembre-2012-4263-avis
2012
false
France
French
ACTIVE CORONARY STENT
Everolimus
Drug-Eluting stents
coronary artery disease
health technology assessment
treatment outcome

---
https://www.ema.europa.eu/medicines/human/EPAR/Votubia
2012
false
United Kingdom
English
French
package leaflet
summary of product characteristics
drug evaluation
syndication feed
Everolimus
Everolimus
orphan drug production
everolimus
administration, oral
astrocytoma
astrocytoma, subependymal giant cell
drug approval
treatment outcome
tuberous sclerosis
drug interactions
pregnancy
breast feeding
TOR Serine-Threonine kinases
protein kinase inhibitors
protein kinase inhibitors
drug evaluation, preclinical
brain neoplasms

---
http://www.has-sante.fr/portail/jcms/c_1192687/votubia
http://www.has-sante.fr/portail/jcms/c_1525543/fr/votubia
2012
false
France
French
Everolimus
administration, oral
insurance, health, reimbursement
everolimus
orphan drug production
adult
child
tuberous sclerosis
treatment outcome
clinical trials as topic
astrocytoma, subependymal giant cell
astrocytoma
brain neoplasms
angiomyolipoma
Angiomyolipoma of kidney (disorder)
evaluation of the transparency committee

---
http://www.has-sante.fr/portail/jcms/c_1238912/votubia-everolimus-inhibiteur-de-la-mtor
http://www.has-sante.fr/portail/jcms/c_1238880/votubia-04012012-synthese-ct11628
http://www.has-sante.fr/portail/jcms/c_1193112/votubia-04012012-ct11628
2012
false
France
French
Everolimus
Everolimus
administration, oral
everolimus
insurance, health, reimbursement
orphan drug production
astrocytoma
astrocytoma, subependymal giant cell
tuberous sclerosis
child
adolescent
adult
brain neoplasms
treatment outcome
clinical trials, phase ii as topic
clinical trials, phase iii as topic
rare diseases
pharmacovigilance
TOR Serine-Threonine kinases
guidelines for drug use
evaluation of the transparency committee

---
http://www.has-sante.fr/portail/jcms/c_1241699/afinitor
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-04/afinitor_28032012_avis_ct11775.pdf
2012
false
France
French
evaluation of the transparency committee
Everolimus
Everolimus
administration, oral
insurance, health, reimbursement
adult
neoplasm metastasis
everolimus
neuroendocrine tumors
pancreatic neoplasms
disease progression
treatment outcome
randomized controlled trials as topic
disease-free survival
survival analysis

---
http://www.has-sante.fr/portail/jcms/c_1350928/gamme-xience-xpedition-endoprothese-coronaire-a-liberation-de-principe-actif
http://www.has-sante.fr/portail/jcms/c_1351201/xience-xpedition-18-decembre-2012-4410-avis
http://www.has-sante.fr/portail/jcms/c_1351207/xience-xpedition-18-decembre-2012-4354-avis
2012
false
France
French
ACTIVE CORONARY STENT
Everolimus
coronary artery disease
Drug-Eluting stents
health technology assessment
treatment outcome

---
http://www.has-sante.fr/portail/jcms/c_1092597/promus-element-plus-13-septembre-2011-3932-avis
http://www.has-sante.fr/portail/jcms/c_1098120/promus-element-plus-13-septembre-2011-3932-avis
2011
false
France
French
health technology assessment
ACTIVE CORONARY STENT
Everolimus
Drug-Eluting stents
coronary artery disease
treatment outcome

---
http://www.has-sante.fr/portail/jcms/c_1068588/xience-v-27-septembre-2011-3857-avis
http://www.has-sante.fr/portail/jcms/c_1100488/xience-v-27-septembre-2011-3857-avis
2011
false
France
French
health technology assessment
ACTIVE CORONARY STENT
Everolimus
Drug-Eluting stents
coronary artery disease
treatment outcome

---
http://www.has-sante.fr/portail/jcms/c_1068582/xience-prime-27-septembre-2011-3859-avis
http://www.has-sante.fr/portail/jcms/c_1100486/xience-prime-27-septembre-2011-3859-avis
2011
false
France
French
health technology assessment
ACTIVE CORONARY STENT
Everolimus
Drug-Eluting stents
coronary artery disease
treatment outcome

---
http://www.has-sante.fr/portail/jcms/c_1058487/promus-14-juin-2011-3832-avis
http://www.has-sante.fr/portail/jcms/c_1064062/promus-14-juin-2011-3832-avis
2011
false
France
French
ACTIVE CORONARY STENT
Everolimus
health technology assessment
Drug-Eluting stents
coronary artery disease
treatment outcome

---
http://www.has-sante.fr/portail/jcms/c_1064064/promus-element-14-juin-2011-3836-avis
http://www.has-sante.fr/portail/jcms/c_1064065/promus-element-14-juin-2011-3836-avis
2011
false
France
French
ACTIVE CORONARY STENT
Everolimus
health technology assessment
Drug-Eluting stents
coronary artery disease
treatment outcome

---
http://www.has-sante.fr/portail/jcms/c_1045976/xience-prime-22-mars-2011-3399-synthese-d-avis
2011
false
France
French
ACTIVE CORONARY STENT
guidelines for medical devices use
health technology assessment
Everolimus
Drug-Eluting stents
coronary artery disease
treatment outcome

---
http://www.has-sante.fr/portail/jcms/c_1045974/xience-v-22-mars-2011-3398-synthese-d-avis
http://www.has-sante.fr/portail/jcms/c_1053203/xience-v-3398-xience-prime-3399-22-mars-2011-synthese-d-avis
2011
false
France
French
ACTIVE CORONARY STENT
health technology assessment
guidelines for medical devices use
Everolimus
Drug-Eluting stents
coronary artery disease
treatment outcome

---
http://www.has-sante.fr/portail/jcms/c_1033013/xience-prime-22-mars-2011-3399-avis
http://www.has-sante.fr/portail/jcms/c_1035150/xience-prime-23-mars-2011-3399-avis
2011
false
France
French
ACTIVE CORONARY STENT
Everolimus
Drug-Eluting stents
coronary artery disease
health technology assessment
treatment outcome

---
https://www.inesss.qc.ca/fileadmin/doc/INESSS/Inscription_medicaments/Avis_au_ministre/ProjetPilote_Cancer/Document_synthese_final_CAV.pdf
2011
false
Canada
French
Pemetrexed
Erlotinib Hydrochloride
Everolimus
drug evaluation
drug evaluation
antineoplastic agents
Cost-Benefit analysis
treatment outcome
insurance, health, reimbursement
carcinoma, renal cell
neoplasm metastasis
pemetrexed
lung neoplasms
canada
gefitinib
everolimus
erlotinib
survival analysis
technical report
drug information
Gefitinib

---
http://www.has-sante.fr/portail/jcms/c_1045967/promus-et-promus-element-12-octobre-2010-3009-synthese-d-avis
2011
false
France
French
ACTIVE CORONARY STENT
health technology assessment
guidelines for medical devices use
Everolimus
Drug-Eluting stents
coronary artery disease
treatment outcome

---
http://www.has-sante.fr/portail/jcms/c_1237197/xience-v-3857-et-xience-prime-3869-27-septembre-2011-synthese-d-avis
http://www.has-sante.fr/portail/jcms/c_1255529/xience-v-3857-xience-prime-3859-27-septembre-2011-synthese-d-avis
2011
false
France
French
health technology assessment
guidelines for medical devices use
ACTIVE CORONARY STENT
Everolimus
Drug-Eluting stents
coronary artery disease
treatment outcome

---
http://www.has-sante.fr/portail/jcms/c_1033010/xience-v-22-mars-2011-3398-avis
http://www.has-sante.fr/portail/jcms/c_1035155/xience-v-23-mars-2011-3398-avis
2011
false
France
French
ACTIVE CORONARY STENT
Everolimus
Drug-Eluting stents
coronary artery disease
health technology assessment
treatment outcome

---
Summary Basis of Decision (SBD) for AFINITOR
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailOne.php?lang=fr&linkID=SBD00003
2010
false
Canada
English
French
Everolimus
antineoplastic agents
neoplasm metastasis
carcinoma, renal cell
canada
drug approval
administration, oral
everolimus
drug information

---
http://www.has-sante.fr/portail/jcms/c_1001631/xience-v-et-xience-prime-29-juin-2010-2532-2533-synthese-d-avis
http://www.has-sante.fr/portail/jcms/c_1016556/xience-v-xience-prime-29-juin-2010-2532-2533-synthese-d-avis
2010
false
France
French
ACTIVE CORONARY STENT
Everolimus
Drug-Eluting stents
coronary artery disease
health technology assessment
guidelines for medical devices use
treatment outcome

---
http://www.has-sante.fr/portail/jcms/c_991919/promus-12-octobre-2010-3009-avis
http://www.has-sante.fr/portail/jcms/c_991921/promus-12-octobre-2010-3009-avis
2010
false
France
French
ACTIVE CORONARY STENT
Everolimus
Drug-Eluting stents
blood vessel prosthesis
coronary artery disease
health technology assessment
treatment outcome

---
http://www.has-sante.fr/portail/jcms/c_973407/xience-prime-29-juin-2010-2532-avis
http://www.has-sante.fr/portail/jcms/c_973409/xience-prime-29-juin-2010-2532-avis
2010
false
France
French
ACTIVE CORONARY STENT
Everolimus
Drug-Eluting stents
coronary artery disease
health technology assessment
treatment outcome

---
http://www.has-sante.fr/portail/jcms/c_973405/xience-v-29-juin-2010-2533-avis
http://www.has-sante.fr/portail/jcms/c_973400/xience-v-29-juin-2010-2533-avis
2010
false
France
French
ACTIVE CORONARY STENT
Everolimus
Drug-Eluting stents
coronary artery disease
health technology assessment
treatment outcome

---
http://www.has-sante.fr/portail/jcms/c_955012/afinitor-everolimus-inhibiteur-de-tyrosine-kinase
http://www.has-sante.fr/portail/jcms/c_955011/synthese-d-avis-afinitor-ct-7009
http://www.has-sante.fr/portail/jcms/c_918364/afinitor-ct-7009
http://www.has-sante.fr/portail/jcms/c_1011527/afinitor-ct-7009-version-anglaise
2010
false
France
French
English
Everolimus
neoplasm metastasis
treatment outcome
carcinoma, renal cell
protein kinase inhibitors
everolimus
orphan drug production
drug approval
insurance, health, reimbursement
administration, oral
intracellular signaling peptides and proteins
Protein Serine-Threonine Kinases
evaluation of the transparency committee

---
http://www.meddispar.fr/medicaments/3962811
2010
false
France
French
Everolimus
tablets
administration, oral
drug prescriptions
legislation, drug
continuity of patient care
drug monitoring
antineoplastic agents
everolimus
drug information

---
http://www.has-sante.fr/portail/jcms/c_940810/promus-element-long-cnedimts-du-23-mars-2010-2504
http://www.has-sante.fr/portail/jcms/c_941548/promus-element-long-cnedimts-du-23-mars-2010-2504
2010
false
France
French
ACTIVE CORONARY STENT
Everolimus
Drug-Eluting stents
immunosuppressive agents
coronary artery disease
health technology assessment
treatment outcome

---
http://www.meddispar.fr/medicaments/3962828
2010
false
France
French
Everolimus
tablets
administration, oral
drug prescriptions
legislation, drug
continuity of patient care
drug monitoring
everolimus
antineoplastic agents
drug information

---
http://www.has-sante.fr/portail/jcms/c_864993/xience-prime-cnedimts-du-22-septembre-2009-2246
http://www.has-sante.fr/portail/jcms/c_864995/xience-prime-cnedimts-du-22-septembre-2009-2246
2009
false
France
French
ACTIVE CORONARY STENT
Everolimus
Drug-Eluting stents
blood vessel prosthesis
coronary artery disease
immunosuppressive agents
health technology assessment
treatment outcome

---
http://www.has-sante.fr/portail/jcms/c_892971/xience-prime-cnedimts-du-08-decembre-2009-2310
http://www.has-sante.fr/portail/jcms/c_892972/xience-prime-cnedimts-du-08-decembre-2009-2310
2009
false
France
French
ACTIVE CORONARY STENT
Everolimus
immunosuppressive agents
Drug-Eluting stents
coronary artery disease
health technology assessment
treatment outcome

---
http://www.has-sante.fr/portail/jcms/c_892686/promus-element-cnedimts-du-08-decembre-2009-2311
http://www.has-sante.fr/portail/jcms/c_892968/promus-element-cnedimts-du-08-decembre-2009-2311
2009
false
France
French
ACTIVE CORONARY STENT
Everolimus
Drug-Eluting stents
immunosuppressive agents
coronary artery disease
health technology assessment
treatment outcome

---
http://www.has-sante.fr/portail/display.jsp?id=c_658717
http://www.has-sante.fr/portail/display.jsp?id=c_658721
2008
false
France
French
ACTIVE CORONARY STENT
Everolimus
Drug-Eluting stents
coronary artery disease
health technology assessment
treatment outcome

---
http://www.meddispar.fr/medicaments/3641159
2008
false
France
French
Everolimus
drug prescriptions
tablets
legislation, drug
administration, oral
immunosuppressive agents
everolimus
drug information

---
http://www.meddispar.fr/medicaments/3641113
2008
false
France
French
Everolimus
immunosuppressive agents
administration, oral
drug prescriptions
legislation, drug
everolimus
drug information

---
http://www.meddispar.fr/medicaments/3641188
2008
false
France
French
Everolimus
immunosuppressive agents
administration, oral
tablets
drug prescriptions
legislation, drug
everolimus
drug information

---
http://www.meddispar.fr/medicaments/3641082
2008
false
France
French
Everolimus
administration, oral
tablets
legislation, drug
immunosuppressive agents
drug prescriptions
everolimus
drug information

---
http://www.meddispar.fr/medicaments/3641030
2008
false
France
French
Everolimus
immunosuppressive agents
administration, oral
tablets
drug prescriptions
legislation, drug
everolimus
drug information

---
https://www.jle.com/fr/revues/medecine/bdc/e-docs/00/04/43/D1/resume.md
2008
false
France
French
corticosteroid therapy
Everolimus
neoplasms
immunosuppressive agents
journal article

---
http://www.has-sante.fr/portail/display.jsp?id=c_572582
2007
false
France
French
ACTIVE CORONARY STENT
Everolimus
immunosuppressive agents
diabetes mellitus
Drug-Eluting stents
coronary stenosis
health technology assessment
treatment outcome

---
http://www.has-sante.fr/portail/display.jsp?id=c_572610
2007
false
France
French
ACTIVE CORONARY STENT
Everolimus
diabetes mellitus
Drug-Eluting stents
coronary stenosis
immunosuppressive agents
health technology assessment
treatment outcome

---
http://www.has-sante.fr/portail/display.jsp?id=c_533159
http://www.has-sante.fr/portail/display.jsp?id=c_533158
2006
false
France
French
Everolimus
Everolimus
immunosuppressive agents
heart transplantation
kidney transplantation
assessment of professional actions

---
https://www.cadth.ca/sites/default/files/pdf/108_No57_everolimus_edrug_f.pdf
2004
false
Canada
French
Everolimus
cyclosporine
drug therapy, combination
graft rejection
heart transplantation
kidney transplantation
clinical trials as topic
immunosuppressive agents
everolimus
drug evaluation

---
Nous contacter.
19/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.